Perspective Therapeutics, Inc.
NYSE · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Perspective Therapeutics is a radiopharmaceutical company developing targeted alpha-particle therapies and imaging agents for cancer treatment, using isotopes such as lead-212 paired with targeting molecules to deliver radiation directly to tumor cells.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Lantheus Alpha Therapy, LLC10% Owner | Sell | $526K | 167,149at $3.15 | Sep 4, 2026 |
| Lantheus Alpha Therapy, LLC10% Owner | Sell | $251K | 80,783at $3.11 | Sep 3, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable CATX activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.